Cantor Fitzgerald Thinks BioDelivery’s Stock is Going to Recover


In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4.50. The company’s shares opened today at $1.95, close to its 52-week low of $1.80.

Folkes observed:

“This morning BDSI announced the appointment of Herm Cukier as CEO, effective 5/8/2018.”

According to TipRanks.com, Folkes is ranked #4578 out of 4778 analysts.

BioDelivery has an analyst consensus of Moderate Buy, with a price target consensus of $4.25.

Find more picks by Best Performing Analysts >>

Based on BioDelivery’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.21 million. In comparison, last year the company had a net profit of $48.33 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts